NEW PPPs FOR BIOMEDICAL RESEARCH
HORIZON 2020
Reflections on IMI to date

• Demonstrated that companies can work together
• Large PPPs are feasible
• Gained lot of experience about what works and what could be improved
• Already showed value – datasets, IP, spinouts

But
• What happens when projects end?
• Still need more SME involvement
• Potential for ‘consortia fatigue’
• Exclusion of other sectors eg devices, mobile etc
IMI Progress Identifiers

**STRENGTHS**
- Cost free interaction and access to scientific excellence
- Data analysis volume and capabilities
  - Access to funding and resources
  - Favorable interaction with regulators

**WEAKNESSES**
- Commitment and maintenance of participants
- Delays: eg. clinical trial & publications
  - IP issues for SMEs & academic spin outs
  - Communication barriers

**CHALLENGES**
- Clarity of project scope
- Balance of consortia size and funding
- Project Management Offices and Work Package (WP) structure
- People reward (eg. academic publications)
- Standardization and reproducibility
- Future project sustainability

**IMPACT**
- Openness and collaboration
  - Trust
- New knowledge
- Open access tools
  - New IP
  - New spin-outs
- Industry standards and clinical qualification of outputs

M. Papadaki 2012
Significant barriers exist in EU to innovation in healthcare

- Few cross-sector mechanisms for funding
- Lack of alignment of evaluation eg for reimbursement
- Many uncertainties
- Lack of commercialisation and access
- These issues are especially acute for SMEs

Bureaucracy
- Lack of integration
- No single IP system
- Inertia to change
- Lack of standards

Funding
- Lack of capital
- Lack of incentives

Impaired innovation capacity
- Legal
- Regulatory
- Reimbursement

Other hurdles
A personal example: fatigue in MS

My patients need a treatment for their fatigue

Patients are too tired to work

New co. has therapy

Patients should work

We won't say if an effective treatment will be reimbursed

No approvable endpoints

VCs and pharma won't invest
Cross-sector recommendations from iNNOVAHEALTH

• Stimulate Open Innovation in healthcare via interlinked initiatives to support the strategy and ensure these are integrated with current initiatives of relevance
• Adopt new funding mechanisms especially to support SMEs and the development of an Open Innovation ecosystem for healthcare
• Decrease regulatory burden and uncertainty
• Increase incentives for collaboration across the value chain
• Accelerate progress to a harmonised EU patent system
Some reflections for the future

• Build on learnings of the past
  – Don’t loose the knowledge, networks, expertise, datasets
• Think BIG and aim HIGH
  – Integrate across initiatives
  – Stimulate cross-sector collaboration to build ecosystem
  – Fund infrastructure
  – Look at wellness and prevention as well as treatment
  – Attempt the impossible
• Address regulatory and access uncertainty especially in new areas
  – Make it easier for new technologies to be commercialised in the EU
  – Make it easier to combine technologies in the EU
• Cross-country as well as cross-company/sector
  – Make it easy/simple
Remembering that....

Problems cannot be solved by thinking within the framework in which the problems were created